Monoamine depletion in psychiatric and healthy populations: Review

Molecular Psychiatry

Volumn 8, Issue 12, 2003, Pages 951-973

  Booij, L ^a   Van Der Does, A J W ^a   Riedel, W J ^b,c,d  

^a LEIDEN UNIVERSITY   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Catecholamine; Challenge; Depletion; Depression; Dopamine; Norepinephrine; Tryptophan

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; AMINO ACID; ANTIDEPRESSANT AGENT; CATECHOLAMINE; CLOMIPRAMINE; COCAINE; DESIPRAMINE; DEXAMPHETAMINE; DIPHENHYDRAMINE; DOPAMINE 2 RECEPTOR; FLUMAZENIL; FLUOXETINE; HOMOVANILLIC ACID; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; LITHIUM; MAZINDOL; METIROSINE; MIRTAZAPINE; MONOAMINE; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT; NORADRENALIN; PHENYLALANINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; VENLAFAXINE;

AGGRESSION; ALCOHOLISM; BEHAVIOR; BIPOLAR DEPRESSION; BULIMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; DYSTONIA; FEMALE; HUMAN; HYPERPROLACTINEMIA; LIGAND BINDING; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MOOD DISORDER; NEUROTRANSMISSION; NORADRENERGIC SYSTEM; PANIC; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; SEASONAL AFFECTIVE DISORDER; TREATMENT OUTCOME;

ALPHA-METHYLTYROSINE; AMINO ACIDS; BIOGENIC MONOAMINES; HUMANS; MENTAL DISORDERS; PSYCHOTIC DISORDERS; REFERENCE VALUES; TRYPTOPHAN;

EID: 0347481324     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001423     Document Type: Review

References (136)

1. Blier P, De Montigny C. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive - compulsive disorder responses. Biol Psychiatry 1998; 44: 313-323.
2. Nutt DJ, Forshall S, Bell C, Rich A, Sandford J, Nash J et al. Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur Neuropsychopharmacol 1999; 9: S81-S86.
3. Young SN, Smith S, Pihl RO, Ervin FR. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology 1985; 87: 173-177.
4. Reilly JG, McTavish SFB, Young AH. Rapid depletion of plasma tryptophan. J Psychopharmacol 1997; 11: 381-392.
5. Delgado PL, Price LH, Miller HL, Salomon RM, Aghajanian GK, Heninger GR et al. Serotonin and the neurobiology of depression. Arch Gen Psychiatry 1994; 51: 865-874.
6. Benkelfat C, Ellenbogen MA, Dean P, Palmour RM, Young SN. Mood-lowering effect of tryptophan depletion. Enhanced susceptibility in young men at genetic risk for major affective disorders. Arch Gen Psychiatry 1994; 51: 687-697.
7. Van Praag HM, Asnis GM, Kahn RS, Brown SL, Korn M, Friedman JM et al. Nosological tunnel vision in biological psychiatry. A plea for a functional psychopathology. Ann NY Acad Sci 1990; 600: 501-510.
8. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 1998; 51: 215-235.
9. Van Praag HM. Faulty cortisol/serotonin interplay: psychopathological and biological characterisation of a new, hypothetical depression subtype (seca depression). Psychiatry Res 1996; 65: 143-157.
10. Riedel WJ, Schoenmakers E, Vermeeren A, O'Hanlon JF. The influence of trazodone treatment on cognitive functions in outpatients with major depressive disorder. Hum Psychopharmacol 1999; 14: 499-508.
11. Robbins TW, Everitt BJ. Limbic-striatal memory systems and drug addiction. Neurobiol Learn Mem 2002; 78: 625-636.
12. Luciana M, Collins PF, Depue RA. Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. Cereb Cortex 2002; 8: 218-226.
13. Cahill L, Prins B, Weber M, McGaugh JL. Beta-adrenergic activation and memory for emotional events. Nature 1994; 371: 702-704.
14. Gijsman HJ, Scarna A, Harmer CJ, McTavish SB, Odontiadis J, Cowen PJ et al. A dose-finding study on the effects of branch chain amino acids on surrogate markers of brain dopamine function. Psychopharmacology (Berl) 2002; 160: 192-197.
15. Van der Does AJW. The effects of tryptophan depletion on mood and psychiatric symptoms. J Affect Disord 2001; 64: 107-119.
16. Carpenter LL, Anderson GM, Pelton GH, Guding JA, Kirwin PD, Price LH et al. Tryptophan depletion during continuous CSF sampling in healthy human subjects. Neuropsychopharmacology 1997; 19: 26-35.
17. Krahn LE, Lu PY, Klee G, Delgado PL, Lin SC, Zimmerman RC. Examining serotonin function: a modified technique for rapid tryptophan depletion. Neuropsychopharmacology 1996; 15: 325-328.
18. Weltzin TE, Fernstrom JD, McConaha C, Kaye WH. Acute tryptophan depletion in bulimia: effects on large neutral amino acids. Biol Psychiatry 1994; 35: 388-397.
19. Wolfe BE, Metzger ED, Jimerson DC. Comparison of the effects of amino acid mixture and placebo on plasma tryptophan to large neutral amino acid ratio. Life Sci 1995; 56: 1395-1400.
20. Booij L, Van der Does AJW, Benkelfat C, Bremner JD, Cowen PJ, Fava M et al. Predictors of mood response to acute tryptophan depletion: a reanalysis. Neuropsychopharmacology 2002; 27: 852-861.
21. Blokland A, Lieben CKJ, Van Oorsouw KIM, Deutz NEP. A new method for lowering plasma tryptophan concentrations: no effect on affective behavior but impaired object memory in rats. Soc Neurosci Abstr 2001; 319.1.
22. Lieben CKJ, Westerink B, Blokland A, Deutz NEP. Acute tryptophan and serotonin depletion using an optimized tryptophan-free protein-carbohydrate mixture in the adult rat. Neurochem Int 2004; 44: 9-16.
23. Blokland A, Lieben C, Deutz NEP. Anxiogenic and depressive-like effects, but no cognitive deficits after repeated moderate tryptophan depletion in the rat. J Psychopharmacol 2002; 16: 39-49.
24. Brown CM, Fletcher PJ, Coscina DV. Acute amino acid loads that deplete brain serotonin fail to alter behavior. Pharmacol Biochem Behav 1998; 59: 115-121.
25. Moreno FA, Gelenberg AJ, Heninger GR, Potter RL, McKnight KM, Allen J et al. Tryptophan depletion and depressive vulnerability. Biol Psychiatry 1999; 46: 498-505.
26. Moreno FA, Heninger GR, McGahuey CA, Delgado PL. Tryptophan depletion and risk of depressive relapse. Biol Psychiatry 2000; 48: 327-329.
27. Leyton M, Ghadirian AM, Young SN, Palmour RM, Blier P, Helmers KF et al. Depressive relapse following acute tryptophan depletion in patients with major depressive disorder. J Psychopharmacol 2000; 14: 84-287.
28. Spillmann MK, Van der Does AJW, Rankin M, Vuolo R, Alpert JF, Nierenberg AA et al. Tryptophan depletion in SSRI-recovered depressed outpatients. Psychopharmacology 2001; 155: 123-127.
29. Johnson L, El-Khoury A, Aberg-Wistedt A, Stain-Malmgren R, Mathe AA. Tryptophan depletion in lithium-stabilized patients with affective disorder. Int J Neuropsychopharmacol 2001; 4: 329-336.
30. Hughes JH, Dunne F, Young AH. Effects of acute tryptophan depletion on mood and suicidal ideation in bipolar patients symptomatically stable on lithium. Br J Psychiatry 2000; 177: 447-451.
31. Benkelfat C, Seletti B, Palmour RM, Hillel J, Ellenbogen M, Young SN. Tryptophan depletion in stable lithium-treated patients with bipolar disorder in remission. Arch Gen Psychiatry 1995; 52: 154-155.
32. Cassidy F, Murray E, Carroll BJ. Tryptophan depletion in recently manic patients treated with lithium. Biol Psychiatry 1998; 43: 230-232.
33. Leyton M, Young SN, Benkelfat C. Relapse of depression after rapid depletion of tryptophan. Lancet 1997; 349: 1840-1841.
34. Van der Does AJW. The mood-lowering effect of tryptophan depletion: possible explanation for discrepant findings. Arch Gen Psychiatry 2001; 58: 200-201.
35. Delgado PL, Charney DS, Price LH, Aghajanian G, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action. Arch Gen Psychiatry 1990; 47: 411-418.
36. Delgado PL, Price LH, Miller HL, Salomon RM, Licinio J, Krystal JH et al. Rapid serotonin depletion as a provocative challenge test for patients with major depression. Psychopharmacol Bull 1991; 27: 321-330.
37. Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH, Moreno FA et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine. Biol Psychiatry 1999; 46: 212-220.
38. 2 receptors: a PET study. Br J Psychiatry 2001; 178: 448-453.
39. Price LH, Malison RT, McDougle CJ, Pelton GH, Heninger GR. The neurobiology of tryptophan depletion in depression: effects of intravenous tryptophan infusion. Biol-Psychiatry 1998; 43: 339-347.
40. Van Praag HM. Serotonin related, anxiety/aggression driven, stressor precipitated depression: a psycho biological hypothesis. Eur Psychiatry 1996; 11: 57-67.
41. Riedel WJ, Sobczak S, Nicolson N, Honig A. Stress, cortisol and memory as markers of serotonergic vulnerability. Acta Neuropsychiatr 2002; 14: 186-191.
42. Moreno FA, Rowe DC, Kaiser B, Chase D, Michaels T, Gelernter J et al. Association between a serotonin transporter promoter region polymorphism and mood response during tryptophan depletion. Mol Psychiatry 2002; 7: 213-216.
43. Neumeister A, Konstantinidis A, Stastny J, Schwarz MJ, Vitouch O, Willeit M et al. Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. Arch Gen Psychiatry 2002; 59: 613-620.
44. Van der Does AJW. The mood-lowering effect of tryptophan depletion: possible explanation for discrepant findings [Letter]. Arch Gen Psychiatry 2001; 58: 200-201.
45. Lerer B, Gelfin Y, Gorfine M, Allolio B, Lesch KP, Newman ME. 5-HT1A receptor function in normal subjects on clinical doses of fluoxetine: blunted temperature and hormone responses to ipsapirone challenge. Neuropsychopharmacology 1999; 20: 628-639.
46. Quested DJ, Sargent PA, Cowen PJ. SSRI treatment decreases prolactin and hyperthermic responses to mCPP. Psychopharmacology 1997; 133: 305-308.
47. Ellenbogen MA, Young SN, Dean P, Palmour RM, Benkelfat C. Acute tryptophan depletion in healthy young women with a family history of major affective disorder. Psychol Med 1999; 29: 35-46.
48. Quintin P, Benkelfat C, Launay JM, Arnulf I, Pointereau-Bellenger A, Barbault S et al. Clinical and neurochemical effect of acute tryptophan depletion in unaffected relatives of patients with bipolar affective disorder. Biol Psychiatry 2001; 50: 184-190.
49. Klaassen T, Riedel WJ, Deutz NEP, Van Praag HM. Mood congruent memory bias induced by tryptophan depletion. Psychol Med 2002; 32: 167-172.
50. Sobczak S, Honig A, Nicolson NA, Riedel WJ. Effects of acute tryptophan depletion on mood and cortisol release in first-degree relatives of type I and type II bipolar patients and healthy matched controls. Neuropsychopharmacology 2002; 27: 834-842.
51. Stewart ME, Deary IJ, Ebmeier KP. Neuroticism as a predictor of mood change: the effects of tryptophan depletion. Br J Psychiatry 2002; 181: 242-247.
52. Neumeister A, Praschak-Rieder N, Hesselmann B, Vitouch O, Rauh M, Barochka A et al. Effects of tryptophan depletion in fully remitted patients with seasonal affective disorder during summer. Psychol Med 1998; 28: 257-264.
53. Lam RW, Bowering TA, Tam EM, Grewal A, Yatham LN, Shiah IS et al. Effects of rapid tryptophan depletion in patients with seasonal affective disorder in natural summer remission. Psychol Med 2000; 30: 79-87.
54. Bell C, Abrams J, Nutt D. Tryptophan depletion: implications for psychiatry. Br J Psychiatry 2001; 178: 399-405.
55. Neumeister A, Konstantinidis A, Praschak-Rieder N, Willeit M, Hilger E, Stastny J et al. Monoaminergic function in the pathogenesis of seasonal affective disorder. Int J Neuropsychopharmacol 2001; 4: 409-420.
56. Van der Does AJW. Acute tryptophan depletion (ATD) induces depressive symptoms [Letter]. Psychol Med 2003; 33: 1133-1134.
57. Kaye WH, Gendall KA, Fernstrom MH, Fernstrom JD, McConaha CW, Weltzin TE. Effects of acute tryptophan depletion on mood in bulimia nervosa. Biol Psychiatry 2000; 47: 151-157.
58. Bell C, Forshall S, Adrover M, Nash J, Hood S, Argyropoulos S et al. Does 5-HT restrain panic? J Psychopharmacol 2002; 16: 5-14.
59. 2-induced anxiety in patients with panic disorder and normal volunteers. Br J Psychiatry 2000; 176: 182-188.
60. Schruers K, Klaassen T, Pols H, Overbeek T, Deutz NEP, Griez E. Effects of tryptophan depletion on carbon dioxide provoked panic in panic disorder patients. Psychiatry Res 2000; 93: 179-187.
61. Petrakis IL, Buonopane A, O'Malley S, Cermik O, Trevisan L, Boutros NN et al. The effect of tryptophan depletion on alcohol self-administration in non-treatment-seeking alcoholic individuals. Alcohol Clin Exp Res 2002; 26: 969-975.
62. Petrakis IL, Trevisan L, Boutros NN, Limoncelli D, Cooney NL, Krystal JH. Effect of tryptophan depletion on alcohol cue-induced craving in abstinent alcoholic patients. Alcohol Clin Exp Res 2001; 25: 1151-1155.
63. Crean J, Richards JB, De Wit H. Effect of tryptophan depletion on impulsive behavior in men with or without a family history of alcoholism. Behav Brain Res 2002; 136: 349-357.
64. Golightly KL, Lloyd JA, Hobson JE, Gallagher P, Mercer G, Young AH. Acute tryptophan depletion in schizophrenia. Psychol Med 2001; 31: 75-84.
65. Bjork JM, Dougherty DM, Moeller FG, Swann AC. Differential behavioral effects of plasma tryptophan depletion and loading in aggressive and nonaggressive men. Neuropsychopharmacology 2000; 22: 357-369.
66. Bond AJ, Wingrove J, Critchlow DG. Tryptophan depletion increases aggression in women during the premenstrual phase. Psychopharmacology 2001; 156: 477-480.
67. Schmeck K, Sadigorsky S, Englert E, Demisch L, Dierks T, Barta S et al. Mood changes following acute tryptophan depletion in healthy adults. Psychopathology 2002; 35: 234-240.
68. Marsh DM, Dougherty DM, Moeller FG, Swann AC, Spiga R. Laboratory-measured aggressive behavior of women: acute tryptophan depletion and augmentation. Neuropsychopharmacology 2002; 26: 660-671.
69. Cleare AJ, Bond AJ. The effect of tryptophan depletion and enhancement on subjective and behavioural aggression in normal male subjects. Psychopharmacology 1995; 118: 72-81.
70. Schmitt JAJ, Jorissen BL, Sobczak S, Van Boxtel MPJ, Hogervorst E, Deutz NEP et al. Tryptophan depletion impairs memory consolidation, but improves focused attention in healthy young volunteers. J Psychopharmacol 2000; 14: 21-29.
71. Riedel WJ, Klaassen T, Deutz NEP, Van Someren A, Van Praag HM. Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. Psychopharmacology 1999; 141: 362-369.
72. Sobczak S, Riedel WJ, Booij L, Aan het Rot M, Deutz NEP, Honig A. Cognition following acute tryptophan depletion: difference between first-degree relatives of bipolar disorder patients and matched healthy control volunteers. Psychol Med 2002; 32: 503-515.
73. Murphy FC, Smith KA, Cowen PJ, Robbins TW, Sahakian BJ. The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers. Psychopharmacology 2002; 163: 42-53.
74. Hughes JH, Gallagher P, Young AH. Effects of acute tryptophan depletion on cognitive function in euthymic bipolar patients. Eur Neuropsychopharmacol 2002; 12: 123-128.
75. Porter RJ, Lunn BS, Walker LLM, Gray JM, Ballard CG, O'Brien JT. Cognitive deficit induced by acute tryptophan depletion in patients with Alzheimer's disease. Am J Psychiatry 2000; 157: 638-640.
76. Porter RJ, Marshall EF, O'Brien JT. Effects of rapid tryptophan depletion on salivary and plasma cortisol in Alzheimer's disease and the healthy elderly. J Psychopharmacol 2002; 16: 73-78.
77. Sjoerdsma A, Engelman K, Spector S. Inhibition of catecholamine synthesis in man with a-methyl-paratyrosine, an inhibitor of tyrosine hydroxylase. Lancet 1965; 2: 1092-1094.
78. Brodie HK, Murphy DL, Goodwin FK, Bunney WE. Catecholamines and mania: the effect of alpha-methyl-para-tyrosine on manic behavior and catecholamine metabolism. Clin Pharmacol Ther 1971; 12: 218-224.
79. Engelman K, Horwitz D, Jequier E, Sjoerdsma A. Biochemical and pharmacologic effects of alpha-methyltyrosine in man. J Clin Invest 1968; 47: 979-986.
80. Bunney WE, Brodie HKH, Murphy DL, Goodwin FK. Studies of alpha-methyl-para-tyrosine, L-dopa, and L-tryptophan in depression and mania. Am J Psychiatry 1971; 127: 872-881.
81. Brogden RN, Heel RC, Speight TM, Avery GS. Alpha-methyl-p-tyrosine: a review of its pharmacology and clinical use. Drugs 1981; 21: 81-89.
82. Shopsin B, Gershon S, Goldstein M, Friedman E, Wilk S. Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients. Psychopharmacol Commun 1975; 1: 239-249.
83. Delgado PL, Miller HL, Salomon RM, Licinio J, Heninger GR, Gelenberg AJ et al. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 1993; 29: 389-396.
84. Krahn LE, Lin SC, Klee GG, Lu PY, Ory SJ, Zimmermann RC. The effect of presynaptic catecholamine depletion on 6-hydroxymelatonin sulfate: a double blind study of alpha-methyl-para-tyrosine. Eur Neuropsychopharmacol 1999; 9: 61-66.
85. Miller HL, Delgado PL, Salomon RM, Heninger GR, Charney DS. Effects of alpha-methyl-para-tyrosine (AMPT) in drug-free depressed patients. Neuropsychopharmacology 1996; 14: 151-157.
86. Anand A, Darnell A, Miller HL, Berman RM, Cappiello A, Oren DA et al. Effect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder. Biol Psychiatry 1999; 45: 972-978.
87. Miller HL, Delgado PL, Salomon RM, Berman R, Krystal JH, Heninger GR et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 1996; 53: 117-128.
88. Delgado PL, Moreno FA, Onate L, Gelenberg AJ. Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients. Int J Neuropsychopharmacol 2002; 5: 63-66.
89. Berman RM, Narasimhan M, Miller HL, Anand A, Cappiello A, Oren DA et al. Transient depressive relapse induced by catecholamine depletion: potential phenotypic vulnerability marker? Arch Gen Psychiatry 1999; 56: 395-403.
90. Neumeister A, Turner EH, Matthews JR, Postolache TT, Barnett RL, Rauh M et al. Effects of tryptophan depletion vs catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. Arch Gen Psychiatry 1998; 55: 524-530.
91. Lam RW, Tam EM, Grewal A, Yatham LN. Effects of alpha-methyl-para- tyrosine-induced catecholamine depletion in patients with seasonal affective disorder in summer remission. Neuropsychopharmacology 2001; 25: S97-S101.
92. Berman RM, Sanacora G, Anand A, Roach LM, Fasula MK, Finkelstein CO et al. Monoamine depletion in unmedicated depressed subjects. Biol Psychiatry 2002; 51: 469-473.
93. Longhurst JG, Carpenter LL, Epperson CN, Price LH, McDougle CJ. Effects of catecholamine depletion with AMPT (alpha-methyl-para-tyrosine) in obsessive-compulsive disorder. Biol Psychiatry 1999; 46: 573-576.
94. 2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000; 97: 7673-7675.
95. 2 binding ratios on SPECT imaging. Neuropsychopharmacology 2001; 25: 642-650.
96. Stine SM, Krystal JH, Petrakis IL, Jatlow PI, Heninger GR, Kosten TR et al. Effect of alpha-methyl-para-tyrosine on response to cocaine challenge. Biol Psychiatry 1997; 42: 181-190.
97. McCann UD, Thorne D, Hall M, Popp K, Avery W, Sing H et al. The effects of L-dihydroxyphenylalanine on alertness and mood in alpha-methyl-para-tyrosine- treated healthy humans. Neuropsychopharmacology 1995; 13: 41-52.
98. 2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997; 17: 162-174.
99. McCann UD, Penetar DM, Shaham Y, Thorne DR, Sing HC, Thomas ML et al. Effects of catecholamine depletion on alertness and mood in rested and sleep-deprived normal volunteers. Neuropsychopharmacology 1993; 8: 345-356.
100. McCann UD, Penetar DM, Belenky G. Acute dystonic reaction in normal humans caused by catecholamine depletion. Clin Neuropharmacol 1990; 13: 565-568.
101. Salomon RM, Miller HL, Krystal JH, Henninger GR, Charney DS. Lack of behavioral effects of monoamine depletion in healthy subjects. Biol Psychiatry 1997; 41: 58-64.
102. Verhoeff NP, Kapur S, Hussey D, Lee M, Christensen B, Papatheodorou G et al. A simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects. Neuropsychopharmacology 2001; 25: 213-223.
103. McCann UD, Penetar DM, Shaham Y, Thorne DR, Gillin JC, Sing HC et al. Sleep deprivation and impaired cognition. Possible role of brain catecholamines. Biol Psychiatry 1992; 31: 1082-1097.
104. Tychsen L, Sitaram N. Catecholamine depletion produces irrepressible saccadic eye movements in normal humans. Ann Neurol 1988; 25: 444-449.
105. Zimmermann RC, Krahn L, Klee G, Lu PY, Ory SJ, Lin SC. The impact of gender on alpha-methyl-para-tyrosine mediated changes in prolactin secretion and 6-hydroxymelatonin sulfate excretion. Psychoneuroendocrinology 1996; 21: 469-478.
106. Zimmermann RC, Krahn L, Klee G, Delgado P, Ory SJ, Lin SC. Inhibition of presynaptic catecholamine synthesis with alpha-methyl-para-tyrosine attenuates nocturnal melatonin secretion in humans. J Clin Endocrinol Metab 1994; 79: 1110-1114.
107. Zimmermann RC, Krahn L, Rahmanie N, Sauer MV. Prolonged inhibition of presynaptic catecholamine synthesis does not alter leptin secretion in normal-weight men and women. Hum Reprod 1998; 13: 822-825.
108. 2 receptor occupancy by endogenous dopamine in healthy humans. Eur J Pharmacol 2000; 387: 179-188.
109. 1, receptor binding in humans. Mol Psychiatry 2002; 7: 322-328.
110. Hindmarch I. Instrumental assessment of psychomotor functions and the effects of psychotropic drugs. Acta Psychiatr Scand Suppl 1994; 380: 49-52.
111. Schmitt JAJ, Ramaekers JG, Kruizinga MJ, Van Boxtel MPJ, Vuurman EFPM, Riedel WJ. Additional dopamine reuptake inhibition attenuates vigilance decrement induced by serotonergic reuptake inhibition in man. J Psychopharmacol 2002; 16: 207-214.
112. Loubinoux I, Pariente J, Boulanouar K, Carel C, Manelfe C, Rascol O et al. A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects. Neuroimage 2002; 15: 26-36.
113. Biggio G, Porceddu ML, Gessa GL. Decrease of homovanillic, dihydroxyphenylacetic acid and cyclic-adenosine-3′,5′-monophosphate content in the rat caudate nucleus induced by the acute administration of an aminoacid mixture lacking tyrosine and phenylalanine. J Neurochem 1976; 26: 1253-1255.
114. Palmour RM, Ervin FR, Baker GB, Young SN. An amino acid mixture deficient in phenylalanine and tyrosine reduces cerebrospinal fluid catecholamine metabolites and alcohol consumption in vervet monkeys. Psychopharmacology 1998; 136: 1-7.
115. Fernstrom MH, Fernstrom JD. Acute tyrosine depletion reduces tyrosine hydroxylation rate in rat central nervous system. Life Sci 1995; 57: 97-102.
116. Moja EA, Lucini V, Benedetti F, Lucca A. Decrease in plasma phenylalanine and tyrosine after phenylalanine-tyrosine free amino acid solutions in man. Life Sci 1996; 24: 2389-2395.
117. McTavish SF, McPherson MH, Harmer CJ, Clark L, Sharp T, Goodwin GM, Cowen PJ. Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness. Br J Psychiatry 2001; 179: 356-360.
118. Leyton M, Young SN, Blier P, Baker GB, Pihl RO, Benkelfat C. A comparison of the effects of acute tryptophan depletion and acute phenylalanine/tyrosine depletion in healthy women. Adv Exp Med Biol 1999; 46: 767-771.
119. Leyton M, Young SN, Pihl RO, Etezadi S, Lauze C, Blier P et al. Effects on mood of acute phenylalanine/tyrosine depletion in healthy women. Neuropsychopharmacology 2000; 22; 52-63.
120. Sheehan BD, Tharyan P, McTavish SFB, Campling GM, Cowen PJ. Use of a dietary manipulation to deplete plasma tyrosine and phenylalanine in healthy subjects. J Psychopharmacol 1996; 10: 231-234.
121. Eriksson T, Wiesel K, Voog L, Hagman M. Diurnal rhythms in rat plasma amino acids. Life Sci 1989; 45: 979-986.
122. Harmer CJ, McTavish SF, Clark L, Goodwinn GM, Cowen PJ. Tyrosine depletion attenuates dopamine function in healthy volunteers. Psychopharmacology 2001; 154: 105-111.
123. Grevet EH, Tietzmann MR, Shansis FM, Hastenpflug C, Santana LC, Forster L et al. Behavioural effects of acute phenylalanine and tyrosine depletion in healthy male volunteers. J Psychopharmacol 2002; 16: 51-55.
124. Leyton M, Young SN, Blier P, Baker GB, Pihl RO, Benkelfat C. Acute tyrosine depletion and alcohol ingestion in healthy women. Alcohol Clin Exp Res 2000; 24: 459-464.
125. McTavish SFB, McPherson MH, Sharp T, Cowen PJ. Attenuation of some subjective effects of amphetamine following tyrosine depletion. J Psychopharmacol 1999; 13: 144-147.
126. McTavish SF, Raumann B, Cowen PJ, Sharp T. Tyrosine depletion attenuates the behavioural stimulant effects of amphetamine and cocaine in rats. Eur J Pharmacol 2001; 20: 115-119.
127. Coupland N, Zedkova L, Sanghera G, Leyton M, Le Melledo JM. Response to pentagastrin after acute phenylalanine and tyrosine depletion in healthy men: a pilot study. J Psychiatry Neurosc 2001; 26: 247-251.
128. Nathan PJ, Harrison BJ, Olver JS, Norman TR, Burrows GD, Stough C. Depletion of serotonin vs dopamine produces double dissociation on tests of mnemonic function in healthy volunteers. Int J Neuropsychopharmacol 2002; 5: S191.
129. Montgomery AJ, Bhagwagar Z, McTavish SFB, Cowen PJ, Grasby PM. Pilot studies of the effect of dietary tyrosine depletion on [C-11]raclopride binding. Schizophrenia Res 2002; 53: S155.
130. Harrison BJ, Olver JS, Norman TR, Nathan PJ. Effects of serotonin and catecholamine depletion on interleukin-6 activation and mood in human volunteers. Hum Neuropsychopharmacol 2002; 17: 293-297.
131. McTavish SFB, Callado L, Cowen PJ, Sharp T. Comparison of the effects of alpha-methyl-p-tyrosine and a tyrosine-free amino acid load on extracellular noradrenaline in the rat hippocampus in vivo. J Psychopharmacol 1999; 13: 379-384.
132. Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive Therapy of Depression. Guilford Press: New York, 1979.
133. Miranda J, Gross JJ, Persons JB, Hahn J. Mood matters: negative mood induction activates dysfunctional attitudes in women vulnerable to depression. Cogn Ther Res 1998; 22: 363-376.
134. Segal ZV, Gemar M, Williams S. Differential cognitive response to a mood challenge following successful cognitive therapy or pharmacotherapy for unipolar depression. J Abnorm Psychol 1999; 108: 3-10.
135. Van der Does AJW. Cognitive reactivity to sad mood: structure and validity of a new measure. Behav Res Ther 2002; 40: 105-120.
136. Van der Does AJW. Thought suppression and cognitive vulnerability to depression. Br J Clin Psychol (in press).